| Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene A Meindl, H Hellebrand, C Wiek, V Erven, B Wappenschmidt, ... Nature genetics 42 (5), 410-414, 2010 | 942 | 2010 |
| Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers MK Graeser, C Engel, K Rhiem, D Gadzicki, U Bick, K Kast, UG Froster, ... Journal of Clinical Oncology 27 (35), 5887-5892, 2009 | 486 | 2009 |
| A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire N Saucedo-Zeni, S Mewes, R Niestroj, L Gasiorowski, D Murawa, ... International journal of oncology 41 (4), 1241-1250, 2012 | 402 | 2012 |
| Management of venous port systems in oncology: a review of current evidence S Vescia, AK Baumgärtner, VR Jacobs, M Kiechle-Bahat, A Rody, S Loibl, ... Annals of Oncology 19 (1), 9-15, 2008 | 382 | 2008 |
| A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC E Gross, N Arnold, J Goette, U Schwarz-Boeger, M Kiechle Human genetics 105, 72-78, 1999 | 338 | 1999 |
| Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator … N Harbeck, RE Kates, MP Look, ME Meijer-van Gelder, JGM Klijn, ... Cancer research 62 (16), 4617-4622, 2002 | 321 | 2002 |
| Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer K Kast, K Rhiem, B Wappenschmidt, E Hahnen, J Hauke, B Bluemcke, ... Journal of medical genetics 53 (7), 465-471, 2016 | 288 | 2016 |
| CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer H Bronger, J Singer, C Windmüller, U Reuning, D Zech, C Delbridge, ... British journal of cancer 115 (5), 553-563, 2016 | 252 | 2016 |
| Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision … N Harbeck, M Schmitt, C Meisner, C Friedel, M Untch, M Schmidt, ... European journal of cancer 49 (8), 1825-1835, 2013 | 230 | 2013 |
| Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer N Harbeck, RE Kates, K Gauger, A Willems, M Kiechle, V Magdolen, ... Thrombosis and haemostasis 91 (03), 450-456, 2004 | 217 | 2004 |
| 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus-opinion of a german team of experts … M Untch*, B Gerber, N Harbeck, C Jackisch, N Marschner, V Möbus, ... Breast care 8 (3), 221-229, 2013 | 196 | 2013 |
| A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers N Arnold, E Gross, U Schwarz‐Boeger, J Pfisterer, W Jonat, M Kiechle Human mutation 14 (4), 333-339, 1999 | 195 | 1999 |
| First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT T Wendler, K Herrmann, A Schnelzer, T Lasser, J Traub, O Kutter, ... European journal of nuclear medicine and molecular imaging 37, 1452-1461, 2010 | 186 | 2010 |
| FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer C Thussbas, J Nahrig, S Streit, J Bange, M Kriner, R Kates, K Ulm, ... Journal of Clinical Oncology 24 (23), 3747-3755, 2006 | 167 | 2006 |
| An automated scoring procedure for the micronucleus test by image analysis D Varga, T Johannes, S Jainta, S Schuster, U Schwarz-Boeger, M Kiechle, ... Mutagenesis 19 (5), 391-397, 2004 | 167 | 2004 |
| Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer N Arnold, L Hägele, L Walz, W Schempp, J Pfisterer, T Bauknecht, ... Genes, Chromosomes and Cancer 16 (1), 46-54, 1996 | 162 | 1996 |
| The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a … K Rhiem, C Engel, M Graeser, S Zachariae, K Kast, M Kiechle, N Ditsch, ... Breast Cancer Research 14, 1-8, 2012 | 160 | 2012 |
| Breastfeeding and breast cancer risk by age 50 among women in Germany J Chang-Claude, N Eby, M Kiechle, G Bastert, H Becher Cancer Causes & Control 11, 687-695, 2000 | 156 | 2000 |
| Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer N Harbeck, RE Kates, M Schmitt, K Gauger, M Kiechle, F Jänicke, ... Clinical breast cancer 5 (5), 348-352, 2004 | 153 | 2004 |
| Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer I Zemzoum, RE Kates, JS Ross, P Dettmar, M Dutta, C Henrichs, ... Journal of Clinical Oncology 21 (6), 1022-1028, 2003 | 149 | 2003 |
